CEACAM8

CEACAM8 (CD66b) is a GPI-anchored, granulocyte-specific glycoprotein that functions as both a cell-surface adhesion/activation receptor and a soluble anti-inflammatory mediator. Stored in specific and gelatinase granules of resting neutrophils, CEACAM8 is mobilized to the cell surface upon activation, where it serves as a galectin-3 receptor and mediates heterophilic adhesion with CEACAM6 through N-terminal domain interactions; its cross-linking activates the Src-family kinase Hck within lipid rafts, induces clustering of the constitutively associated β2-integrin CD11b/CD18, triggers calcium-dependent upregulation of integrin-mediated adhesion, superoxide production, degranulation, and directed release of preformed IL-8 (PMID:8699114, PMID:8645267, PMID:10553088, PMID:11590190, PMID:18056392, PMID:17002897). In its soluble form, released via TLR9-dependent signaling in response to bacterial DNA or extracellular chromatin, CEACAM8 binds CEACAM1 on pulmonary epithelial cells, phosphorylates the CEACAM1 ITIM, recruits the phosphatase SHP-1, and thereby dampens TLR2-dependent PI3K-Akt pro-inflammatory signaling (PMID:24743304, PMID:31258530). Granulocyte-restricted expression is directed by cis-regulatory elements within the CGM6 locus, with expression initiating in fetal liver hematopoiesis (PMID:9427723).

1. 1992 Medium

   Establishing that CEACAM8 is GPI-anchored resolved how a CEA-family member lacking a transmembrane domain is tethered to the granulocyte surface and set the stage for understanding its signaling through lipid-raft-associated partners rather than an intrinsic cytoplasmic tail.

   Evidence PI-PLC cleavage from granulocytes with SDS-PAGE/immunoblot confirmation of released ~38 kDa deglycosylated core

   PMID:1370882

   Open questions at the time

   • Mechanism by which a GPI-anchored protein without a cytoplasmic domain transduces signals was unknown
   • Whether GPI anchorage was required for function in vivo was untested
2. 1996 High

   Demonstrating that CEACAM8 engagement triggers calcium-dependent upregulation of CD11/CD18-mediated neutrophil adhesion to endothelium, and that CEACAM8 mediates heterophilic binding with CEACAM6 via N-terminal domains, established its dual role as an adhesion molecule and activation receptor on granulocytes.

   Evidence Anti-CD66b mAb stimulation of neutrophils with HUVEC adhesion assay plus calcium chelation/CD18 blocking; recombinant protein binding assays with CHO transfectants and N-domain blocking antibodies

   PMID:8645267 PMID:8699114

   Open questions at the time

   • The downstream kinase signaling pathway was unidentified
   • Physical association between CEACAM8 and integrins was not yet demonstrated
3. 1998 Medium

   Identifying that all cis-regulatory elements for granulocyte-restricted expression reside within a 16.5 kb CGM6 cosmid explained the lineage-specific expression pattern and showed that CEACAM8 expression begins during fetal hematopoiesis.

   Evidence Transgenic mice carrying human CGM6 cosmid, with Northern blot, immunohistochemistry, and FACS confirming granulocyte-restricted expression from fetal day 12.5

   PMID:9427723

   Open questions at the time

   • Specific transcription factors driving granulocyte-restricted expression were not identified
   • Regulatory elements were not mapped to individual promoter/enhancer regions
4. 1999 High

   Identifying CEACAM8 as a major galectin-3 receptor stored in gelatinase and specific granules, and showing that its cross-linking induces CD11b clustering via a mannose-sensitive lectin-like interaction, connected granule mobilization to integrin-dependent effector functions.

   Evidence Galectin-3-Sepharose affinity chromatography of neutrophil granule fractions; immunofluorescence of CD66b/CD11b co-redistribution after cross-linking with D-mannose inhibition

   PMID:10233903 PMID:10553088

   Open questions at the time

   • Whether galectin-3 binding directly triggers CD11b clustering or acts through an intermediate was unclear
   • Nature of the CD66b–CD11b physical interaction was unresolved
5. 2001 High

   Systematic mutagenesis established that CEACAM8 engages exclusively in heterophilic (not homophilic) adhesion with CEACAM6, with critical contact residues in the N-domain overlapping but distinct from those used in CEACAM6 homophilic binding, defining the structural basis of selectivity.

   Evidence Homologue-scanning mutagenesis of CEACAM6 in CHO transfectants paired with CEACAM8-expressing cells in cell adhesion assays

   PMID:11590190

   Open questions at the time

   • No crystal structure of the CEACAM8–CEACAM6 N-domain complex
   • Functional consequence of heterophilic vs. homophilic preference in vivo was untested
6. 2006 Medium

   Showing that CEACAM8 cross-linking triggers directed release of preformed IL-8 without de novo synthesis revealed a rapid, degranulation-coupled cytokine mobilization pathway distinct from transcription-dependent inflammatory responses.

   Evidence CD66b mAb cross-linking of human neutrophils with intracellular IL-8 detection by ELISA, compared to LPS-induced de novo synthesis

   PMID:17002897

   Open questions at the time

   • Signaling intermediates linking CD66b engagement to IL-8 granule exocytosis were not identified
   • Whether this pathway operates in vivo during infection was untested
7. 2007 High

   Demonstrating that CEACAM8 resides in lipid rafts, is constitutively associated with CD11b, and signals through Hck upon engagement by galectin-3 provided the missing signaling mechanism for a GPI-anchored protein lacking an intrinsic cytoplasmic domain.

   Evidence Co-immunoprecipitation of CD66b with CD11b, Hck kinase activation assay, lipid raft disruption with methyl-β-cyclodextrin, GPI removal by PI-PLC, immunofluorescence in eosinophils

   PMID:18056392

   Open questions at the time

   • Whether Hck activation is direct or requires an adaptor bridging CD66b to intracellular kinases was unresolved
   • Structural basis of the constitutive CD66b–CD11b association was unknown
8. 2014 High

   Discovering that soluble CEACAM8 binds epithelial CEACAM1, phosphorylates its ITIM, recruits SHP-1, and suppresses TLR2-PI3K-Akt signaling established a granulocyte-derived anti-inflammatory paracrine circuit—the first defined function for the secreted form of CEACAM8.

   Evidence CEACAM8-Fc binding to CEACAM1+ epithelial cells, co-IP for SHP-1 recruitment, phospho-ITIM detection, TLR2/PI3K-Akt pathway analysis, BALF validation

   PMID:24743304

   Open questions at the time

   • Whether soluble CEACAM8 binds CEACAM1 in the same N-domain orientation as cell-surface heterophilic interactions was unknown
   • In vivo relevance of this anti-inflammatory circuit in infection resolution was not tested in animal models
9. 2019 Medium

   Identifying extracellular chromatin as a stimulus for soluble CEACAM8 secretion (via both degranulation and de novo synthesis) linked sterile inflammation and NETosis to the CEACAM8-mediated anti-inflammatory pathway, and elevated synovial fluid levels in RA patients implied clinical relevance.

   Evidence Primary PMN stimulation with mono-nucleosomes and long chromatin, ELISA, inhibitor dissection of synthesis vs. degranulation, RA synovial fluid analysis

   PMID:31258530

   Open questions at the time

   • Receptor or sensor on neutrophils mediating chromatin-induced CEACAM8 release was not identified
   • Whether elevated soluble CEACAM8 in RA fluid is protective or a disease biomarker was not established
   • Single-lab finding; independent replication of chromatin-triggered secretion pathway needed

• Key unresolved questions include the structural basis of the CEACAM8–CD11b constitutive complex, the adaptor mechanism linking GPI-anchored CEACAM8 to Hck activation, the in vivo role of the soluble CEACAM8–CEACAM1 anti-inflammatory axis during infection, and the chromatin-sensing pathway that triggers CEACAM8 release.
• No structural model of the CEACAM8–CD11b or CEACAM8–CEACAM6 complex
• No genetic loss-of-function model (CEACAM8 is absent in rodents except as a transgene)
• Adaptor linking GPI-anchored CEACAM8 to intracellular kinase Hck is unknown